Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prospective Validation of the OHI Index
Sponsor: Meir Medical Center
Summary
Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.
Official title: A Prospective Study to Validate the Prognostic Power of the Optimized HLH Inflammatory (OHI) Index
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2021-03-03
Completion Date
2030-03-03
Last Updated
2025-05-13
Healthy Volunteers
Yes
Conditions
Locations (2)
Meir Medical Center
Kfar Saba, Israel
Rabin Medical Center
Petah Tikva, Israel